Please login to the form below

Not currently logged in
Email:
Password:

Verona appoints chief financial officer

Richard Bungay brings experience from Chroma, Celltech and AstraZeneca

Verona Pharma Richard BungayVerona has named Richard Bungay as the company's chief financial officer to replace Danny Lowe.

Bungay joins the UK-based biotech initially on a part-time basis as it looks to develop its portfolio of investigational medicines for respiratory diseases.

His most recent position was as part-time CEO of fellow UK biotech Chroma Therapeutics, which focuses on the development of novel small molecules for inflammation and oncology, having previously served as the company's chief financial officer.

Prior to his time at Chroma, Bungay was director of corporate communications and strategic planning at Celltech and spent several years as finance director within the respiratory and inflammation therapy area at AstraZeneca.

Dr Jan-Anders Karlsson, CEO of Verona Pharma, said: "Richard's experience in financial management of innovative R&D-based businesses as well as his experience in investor relations will be invaluable to Verona Pharma as we move our key clinical programmes forward and grow the company.”

10th September 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Guide
How to embrace behavioural science principles in healthcare MR...
Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...